By disposing of the abundant ubiquitinated proteins MARCKS was observed to prolong therapeutic resistance by possibly circumventing unfolded protein response which is also a common occurrence in other bortezomib-resistant blood cancers [158–160]. Here, MARCKS is linked to hematopoietic and lymphoid system neoplasm.